PMID- 24964759
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20141121
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
VI  - 124
IP  - 12
DP  - 2014 Dec
TI  - Long-term hearing loss after chemoradiation in patients with head and neck 
      cancer.
PG  - 2720-5
LID - 10.1002/lary.24802 [doi]
AB  - OBJECTIVES/HYPOTHESIS: The purpose of this study was to determine whether 
      concomitant chemoradiation (CCRT)-induced hearing loss is progressive over time 
      or not. STUDY DESIGN: Long-term (LT) follow-up study. METHODS: Between 1999 and 
      2004, 158 patients with head and neck cancer were treated with intravenous (IV) 
      CCRT (n = 80) or intraarterial CCRT (n = 78). Audiometry was performed before, 
      short-term (ST), and LT posttreatment. Differences in hearing were assessed with 
      a multivariable linear regression analysis, incorporating the effect of aging. 
      RESULTS: Long-term audiometry (median 4.5 years) was available in 67 patients 
      (42%). At ST follow-up, a deterioration of 21.6 decibel was seen compared to 
      baseline at pure-tone averages (PTA) 8-10-12.5 kHz. At LT follow-up, this 
      deterioration further increased with 5 decibel (P = 0.005). Only in CCRT-IV 
      patients was a significant progressive treatment-induced hearing loss seen, at 
      PTA 8-10-12.5 kHz (P = 0.005), PTA 1-2-4 kHz air conduction (P = 0.014), and PTA 
      0.5-1-2 kHz bone conduction (P = 0.045). CONCLUSION: CCRT-induced hearing 
      impairment was progressive over time, especially in higher frequencies and only 
      in CCRT-IV patients, with a modest deterioration of 5 decibel 4.5 years 
      post-treatment. LEVEL OF EVIDENCE: 4.
CI  - (c) 2014 The American Laryngological, Rhinological and Otological Society, Inc.
FAU - Theunissen, Eleonoor A R
AU  - Theunissen EA
AD  - Department of Head and Neck Oncology and Surgery, Academic Medical Center, 
      University of Amsterdam, Amsterdam, The Netherlands.
FAU - Zuur, Charlotte L
AU  - Zuur CL
FAU - Bosma, Sophie C J
AU  - Bosma SC
FAU - Lopez-Yurda, Marta
AU  - Lopez-Yurda M
FAU - Hauptmann, Michael
AU  - Hauptmann M
FAU - van der Baan, Sieberen
AU  - van der Baan S
FAU - de Boer, Jan Paul
AU  - de Boer JP
FAU - van der Molen, Lisette
AU  - van der Molen L
FAU - Rasch, Coen R N
AU  - Rasch CR
FAU - Dreschler, Wouter A
AU  - Dreschler WA
FAU - Balm, Alfons J M
AU  - Balm AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140626
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Audiometry, Pure-Tone
MH  - Auditory Threshold/physiology
MH  - Chemoradiotherapy/adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - *Forecasting
MH  - Head and Neck Neoplasms/*drug therapy/*radiotherapy
MH  - Hearing/*physiology/*radiation effects
MH  - Hearing Loss/diagnosis/epidemiology/*etiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Retrospective Studies
MH  - Time Factors
OTO - NOTNLM
OT  - Chemoradiation
OT  - cisplatin
OT  - head and neck cancer
OT  - hearing loss
OT  - ototoxicity
EDAT- 2014/06/27 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/06/27 06:00
PHST- 2014/03/05 00:00 [received]
PHST- 2014/04/23 00:00 [revised]
PHST- 2014/06/03 00:00 [accepted]
PHST- 2014/06/27 06:00 [entrez]
PHST- 2014/06/27 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - 10.1002/lary.24802 [doi]
PST - ppublish
SO  - Laryngoscope. 2014 Dec;124(12):2720-5. doi: 10.1002/lary.24802. Epub 2014 Jun 26.